ZLAB · Zai Lab Limited

The thesis

Zai Lab's case for a global re-rating rests on first-line small-cell lung cancer data for its DLL3-targeted drug zocilurtatug pelitecan (zoci), due at the European Society for Medical Oncology (ESMO) Congress on 26 October 2026. A registrational Phase 3 start announced by 31 December 2026 would confirm the case. A delay past that date would break it.

Zoci is an antibody-drug conjugate (ADC), a drug that uses an antibody to carry a toxic payload into cancer cells. The poster, abstract 1569 on poster board 3817P, covers zoci plus atezolizumab with or without carboplatin. It runs on 26 October 2026 in Madrid. The investor call is on 23 October 2026 at 8:00 a.m. ET, according to the company's 29 September 2026 release. Zai Lab release

The shares closed at $23.10 on 13 October 2026, down from $24.59 on 12 October 2026, according to adjusted daily closes. Company news and filings show no new event behind the drop, and no first-line efficacy numbers have been released before the poster. The move changes the price, not the business case: the readout and the Phase 3 timetable still decide it.

On the 6 August 2026 earnings call, management said the poster would cover about 60 patients with a median follow-up of 8 to 9 months, most of them on the doublet with a checkpoint inhibitor at the top 1.6 mg/kg dose. It expects three registrational zoci programs underway by the end of 2026: two in small-cell lung cancer and one in neuroendocrine carcinoma. The Q2 2026 release says the first-line Phase 3 start in the second half of 2026 depends on "emerging data and regulatory discussions". Q2 2026 call transcript, AOL · Q2 2026 results release

The narrative is maturing: the ESMO date has been public since 29 September 2026, and the American depositary shares (ADS) have slid since, from a $25.58 close on 6 October 2026 to $23.10 on 13 October 2026. Zoci's poster will be read against Amgen's tarlatamab, a DLL3-targeted T-cell engager, whose Phase 3 DeLLphi-305 first-line maintenance trial is late-breaking abstract LBA3 at the same congress, according to OncoDaily on 1 October 2026. OncoDaily

Bullish and bearish views on Zai Lab Limited

The bull case on Zai Lab Limited (ZLAB), in brief: The readout has meaningful follow-up. The bear case: Amgen may raise the first-line bar.

Bull case

• The readout has meaningful follow-up. About 60 patients with 8 to 9 months of median follow-up, as management described on the 6 August 2026 call, is long enough to show whether responses hold.
• A second-line registrational trial is already running. Pulse 2.0 reported on 9 August 2026 that the global Phase 3 DLLEVATE study in second-line and later extensive-stage small-cell lung cancer (ES-SCLC) expects to finish enrollment in the first half of 2027. The company targets its first US regulatory submission in 2027. Pulse 2.0
• Regulators have granted three designations. The US Food and Drug Administration (FDA) granted zoci Fast Track for extrapulmonary neuroendocrine carcinomas on 11 May 2026 and Orphan Drug Designation for neuroendocrine carcinomas in July 2026. The European Medicines Agency granted orphan status for pulmonary neuroendocrine carcinomas in June 2026. Business Wire
• The balance sheet funds the program. The company ended the second quarter of 2026 with $717.5 million in cash, according to the 6 August 2026 call.
• The pre-event premium has partly unwound. The 14-day relative strength index (RSI), a momentum gauge, stood at 31.4 on 13 October 2026, near the 30 level usually read as oversold, with the shares 26.0% below the $31.23 52-week high.

Bear case

• Amgen may raise the first-line bar. DeLLphi-305 is a Phase 3 trial presented as a late-breaker at the same congress, per OncoDaily on 1 October 2026. A survival gain for tarlatamab maintenance would set the comparator any zoci Phase 3 must beat.
• The first-line data are early and small. The poster is a Phase 1b/1c cohort of about 60 patients, per the 6 August 2026 call. Combination toxicity with carboplatin could slow the move into Phase 3.
• The Phase 3 start is conditional. The Q2 2026 release ties the second-half 2026 start to "emerging data and regulatory discussions", which leaves room for a delay.
• Commercial revenue is soft year on year. Second-quarter 2026 net product revenue was $105.8 million, below $109.1 million a year earlier, according to the Q2 2026 release, though Investing.com's summary of the Q2 slides put the sequential gain at 7%. Investing.com
• Selling has run ahead of the data. The shares fell from $25.58 on 6 October 2026 to $23.10 on 13 October 2026 with no company news, per adjusted daily closes.

Price setup

The ADS closed at $23.10 on 13 October 2026, 26.0% below the $31.23 52-week high and up 11.3% over three months, according to adjusted daily closes. The 14-day RSI was 31.4. The shares closed at $24.59 on 12 October 2026 and $25.58 on 6 October 2026, so most of the October decline came before any first-line data were public.

The $22 level sits below the last close. A weekly close under it would mean the October slide had extended through the investor call and the poster. The Hong Kong-listed ordinary shares (9688) trade first each day and set the overnight reference.

Crowding is light by the observable measures: the RSI is near oversold, the shares sit well below their high, and SEC filings show no new share issuance in the last 30 days. The main crowding factor is timing, with the investor call and the poster both inside the next two weeks.

Catalysts, next 30 days

• 23 October 2026, 8:00 a.m. ET — Investor call on zoci first-line data and clinical plans. Management's first chance to restate or move the first-line Phase 3 timetable.
• 23 October to 27 October 2026 — ESMO Congress 2026; Amgen's DeLLphi-305 (LBA3) is presented in this window (~24 October 2026, est.). It sets the first-line comparator for DLL3 drugs.
• 26 October 2026 — ESMO poster, abstract 1569: zoci plus atezolizumab with or without carboplatin in first-line ES-SCLC. The first global first-line efficacy and safety data.
• ~5 November 2026, est. — Third-quarter 2026 results. The company has not yet announced the date; it reported the third quarter of 2025 on 6 November 2025. Shows whether product revenue has recovered against the prior-year quarter.
• 31 December 2026 — End of the second-half 2026 window for the first-line zoci Phase 3 start. The case depends on an announced start by this date.

What would change the view

The case breaks if management moves the first-line registrational Phase 3 start beyond 2026, whether on the 23 October 2026 call, after the 26 October 2026 poster, or by silence through 31 December 2026. A safety signal in the carboplatin triplet that forces a dose or regimen change would weaken it. So would a clear overall survival benefit for tarlatamab in DeLLphi-305 that leaves little room for a second DLL3 drug in first-line treatment.

On price, a weekly close below $22 would show that the market has rejected the readout or the timetable. The case strengthens if the 23 October 2026 call confirms a second-half 2026 Phase 3 start with a named design and comparator, and if third-quarter product revenue exceeds the prior-year quarter.

What it trades with

The ADS trade alongside Hong Kong-listed ordinary shares under 9688, so Hong Kong biotech sentiment carries into the US session. The zoci read is tied to Amgen's tarlatamab: both target DLL3 in small-cell lung cancer, and their ESMO 2026 presentations fall in the same congress window. Product revenue comes from Greater China, so China's drug-pricing decisions bear on the commercial side independent of the zoci data.